Press Releases

04/04/2022
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Topline Results from the 24-Month Phase III BALANCE Clinical Trial of PRX-102 for the Treatment of Fabry Disease
PRX-102 successfully met the primary endpoint on kidney function in active control, non-inferiority study vs. agalsidase beta
Topline results demonstrated a favorable tolerability and immunogenicity profile for PRX-102 BLA resubmission planned for the second half of 2022

31/03/2023
Chiesi Global Rare Diseases Announces Approval of FERRIPROX™ MR Deferiprone Extended-Release Tablets in Canada.
US Resident: Please refer to the Ferriprox (deferiprone) Important Safety Information and Boxed Warning concerning Agranulocytosis and Neutropenia and Full Prescribing Information at www.ferriprox.com/isi
BOSTON, March 31, 2023 – Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases, today announced that Health Canada has approved FERRIPROX™ MR deferiprone extended-release tablets 1 000 mg for the treatment of patients...
Thoughts from our Leaders
Recent Articles
Join our rare community
Learn More about Chiesi Global Rare Diseases

See
Products
Discover treatments that are helping to change the rare disease landscape.

Find
Treatments
Discover innovative treatments that are helping to change the rare disease landscape.

See
Pipeline
Explore rare disease therapies under development.

See
Pipeline
Explore novel therapies under development.

For Healthcare
Professionals
From research to results, see how we’re committed to helping you help your patients.

For
Patients
Find support, advocacy, and what we value most—a caring community.